GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug

Core Insights - Monte Rosa Therapeutics (GLUE) experienced a 45.41% increase in share price following positive interim data from a phase-I study of its candidate MRT-8102, aimed at treating inflammatory conditions driven by NLRP3, IL-1, and IL-6 [1][6] Study Results - The phase I MRT-8102 study is a randomized, double-blind, placebo-controlled trial involving healthy volunteers and higher cardiovascular-risk subjects, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamic effects [2] - Interim results showed robust activity of MRT-8102, with 48 patients in single-dose cohorts, 40 in multiple-dose cohorts, and 24 higher-risk patients completing four weeks of treatment [5] - MRT-8102 achieved approximately 80–90% NEK7 degradation across all dose levels [5][6] - High-sensitivity CRP (hsCRP) levels were reduced by 85% in the higher-risk group after four weeks, with nearly all patients reaching low-risk levels [6] Safety and Tolerability - The drug demonstrated a favorable safety profile and was well-tolerated among participants [7] Future Development Plans - Monte Rosa plans to report complete data from the GFORCE-1 study in the first half of 2026 and initiate the phase II GFORCE-2 study later in the year [8] - The company expects partner Novartis to start multiple mid-stage studies of MRT-6160 in immune-related diseases in 2026 [8] - Additional plans include presenting updated data from the ongoing phase I/II study of MRT-2359 at the ASCO Genitourinary Cancers Symposium in February 2026 and initiating the MODeFIRe-1 phase II study later in the year [9] - Monte Rosa intends to submit IND applications in 2026 for next-generation NEK7-directed MGD and a CDK2 and/or cyclin E1-directed MGD [9]